Promoting the removal of pathological tau via microglia or through intracellular degradation pathways like the proteasome. Key Therapeutic Strategies
Small Phase I studies have shown ASOs are safe and can reduce aggregated tau. Current Challenges and Clinical Status antitauon
Using antibodies to bind to extracellular tau species, preventing them from being taken up by healthy neighboring neurons. Promoting the removal of pathological tau via microglia
Current research focuses on both to combat these tauon species: Example Agents / Trials Passive Immunotherapy ACI-35 Intracellular Targeting
Vaccines that stimulate the patient's own immune system to produce anti-tau antibodies. , ACI-35 Intracellular Targeting